NasdaqCM - Delayed Quote USD

Oramed Pharmaceuticals Inc. (ORMP)

2.3500

+0.0200

(+0.86%)

At close: April 23 at 4:00 PM EDT

Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation

PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has paid off the remaining balance of approx. $1,300,000 under the convertible debentures (the “Convertible Debentures”) previously issued and sold to YA II PN, Ltd. (“Yorkville”) in March 2023. Sci

GlobeNewswire last month

SCLX

SCLXW

ORMP
+0.86%
Oramed Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

Oramed Pharmaceuticals ( NASDAQ:ORMP ) Full Year 2023 Results Key Financial Results Net income: US$5.53m (up from...

Simply Wall St. last month

ORMP
+0.86%
Oramed Letter to Shareholders

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.

PR Newswire 2 months ago

ORMP
+0.86%
ORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery Platform

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT JV with HTIT to help commercialize assets… Oramed Pharmaceuticals (NASDAQ:ORMP) entered into an agreement with Hefei Tianhui Biotech earlier this month to establish a joint venture (JV) based on Oramed’s oral drug delivery technology focused on developing and commercializing innovative products based on Oramed's oral insulin and POD™

Zacks Small Cap Research 2 months ago

ORMP
+0.86%
Oramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year ago

Investing in stocks comes with the risk that the share price will fall. And there's no doubt that Oramed...

Simply Wall St. 6 months ago

ORMP
+0.86%
ORMP: Distribution Deals, JVs in Anticipation of Commercializing ORMD-0801

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT JV with HTIT to help commercialize ORMD–0801 … Oramed Pharmaceuticals (NASDAQ:ORMP) continues to advance its proprietary oral protein delivery platform and is researching the technology potentially to treat diabetes, NASH (nonalcoholic steatohepatitis (NASH), and obesity, as an appetite suppressant, and a COVID vaccine, among other

Zacks Small Cap Research 6 months ago

ORMP
+0.86%
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company

Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "Company"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, announced the consummation on September 21, 2023, of the previously announced sale to Scilex Holding Company (Nasdaq: SCLX, "Scilex") of certain securities that Sorrento held in Scilex.

PR Newswire 6 months ago

ORMP
+0.86%
SRNEQ

SCLX
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE:ORMP) today announced that on September 21, 2023, Oramed and Scilex Holding Company ("Scilex") entered into a Securities Purchase Agreement pursuant to which Scilex issued a Senior Secured Promissory Note (the "Note") to Oramed. The Note is the culmination of Scilex's assumption of Sorrento Therapeutics Inc.'s ("Sorrento") approximately $100 million senior secured Debtor In Possession ("DIP") term loan facility with Oramed. Oramed previously annou

PR Newswire 6 months ago

ORMP
+0.86%
Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.

PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”). Pursuant to that certain Stock Purchase Agreement entered into on Septem

GlobeNewswire 6 months ago

SCLX

ORMP
+0.86%
SRNEQ
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder

PALO ALTO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. (Nasdaq: ORMP, “Oramed”) and Sorrento executed non

GlobeNewswire 7 months ago

ORMP
+0.86%
SCLX

SRNEQ
Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com) announced today that it has signed a non-binding term sheet with Hefei Tianhui Biotech Co., Ltd. ("HTIT") to establish a joint venture ("JV") based on Oramed's oral drug delivery technology. The proposed JV would focus on the development and worldwide commercialization of innovative products based on Oramed's oral insulin and POD™ (Protein Oral Delivery) pipeline and HTIT's manufacturing capabilities and technologies. The J

PR Newswire 8 months ago

ORMP
+0.86%
Oramed to Present at the 83rd American Diabetes Association Conference

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it has been selected to present an oral abstract presentation at the American Diabetes Association's 83rd Scientific Sessions, taking place between June 23-26, 2023 in San Diego, California.

PR Newswire 9 months ago

ORMP
+0.86%
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. 10 months ago

ORMP
+0.86%
ORMP: Advancing Development Efforts in China

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Licensing deal – potential royalty payments if product is commercialized in China … Earlier this month, Oramed Pharmaceuticals’ (NASDAQ:ORMP) partner in China, Hefei Tianhui Biotechnology Co. (HTIT), completed a Phase 3 oral insulin clinical trial in China and, based on the results, submitted a marketing authorization application to

Zacks Small Cap Research 10 months ago

ORMP
+0.86%
Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Novel Therapies for Type 2 Diabetes & Obesity Summit in Boston, MA, on May 31, 2023. The presentation will include an overview of Oramed's oral delivery technology as well as insights from the Company's recent Phase 3 oral insulin clinical trials.

PR Newswire 11 months ago

ORMP
+0.86%
Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) announced today that Hefei Tianhui Biotechnology Co. Ltd. (HTIT), a strategic partner of Oramed, has successfully completed its Phase 3 trials of oral insulin in type 2 diabetes in China under a differentiated study protocol. HTIT is now moving toward regulatory approval and has submitted the data to the National Medical Products Administration (NMPA, formerly the CFDA).

PR Newswire 11 months ago

ORMP
+0.86%
Oramed Appoints Ben Shapiro to its Board of Directors

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the "Company") (www.oramed.com) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023. The Board determined that Mr. Shapiro qualifies as an independent director under the listing rules of the Nasdaq Capital Market.

PR Newswire 11 months ago

ORMP
+0.86%

Performance Overview

Return	ORMP	S&P 500
YTD	+1.73%	+6.30%
1-Year	+2.17%	+22.67%
3-Year	-74.87%	+22.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Oramed Pharmaceuticals Inc. (ORMP)

Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation

Oramed Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

Oramed Letter to Shareholders

ORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery Platform

Oramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year ago

ORMP: Distribution Deals, JVs in Anticipation of Commercializing ORMD-0801

Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.

Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

Oramed to Present at the 83rd American Diabetes Association Conference

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

ORMP: Advancing Development Efforts in China

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

Oramed Appoints Ben Shapiro to its Board of Directors

Performance Overview